Biosimilars: Review of current applications, obstacles, and their future in medicine

doi:10.12998/wjcc.v6.i8.161

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9495)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

605

WORD

348

HTML

5394

Tables (1-1)

619

Sum=6966

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1070

Download

1460

Sum=2530

Aug 16, 2018 (publication date) through Nov 25, 2025

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Editorial

World J Clin Cases. Aug 16, 2018; 6(8): 161-166
Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.161

Table 1 Biologics approved for the management of gastrointestinal inflammatory and oncological conditions

Condition/disease	Biologic	FDA approved biosimilar
Crohn’s disease	Infliximab (anti-TNFα)	Remsima, Inflectra, Renflexis, Flixabi
	Adalimumab (anti-TNFα)	Amjevita, Cyltezo
	Certolizumab (anti-TNFα)	NA
	Vedolizumab (anti-α4-integrin)	NA
	Natalizumab (anti-α4-integrin)	NA
	Ustekinumab (anti-IL-antibody)	NA
Ulcerative colitis	Infliximab (anti-TNFα)	Remsima, Inflectra, Renflexis, Flixabi
	Adalimumab (anti-TNFα)	Amjevita, Cyltezo
	Golimumab (anti-TNFα)	NA
Colorectal cancer	Bevacizumab (anti-VEGF)	Mvasi
	Ramucirumab (anti-VEGF)	NA
	Cetuximab (anti-EGFR)	NA
	Pantimumab (anti-EGFR)	NA
Gastric cancer	Trastuzumab (anti-HER2/neu)	Ogivri

VEGF: Vascular endothelial growth factor; IL: Interleukin; EGFR: Epidermal growth factor receptor; NA: An FDA approved biosimilar is not available.

Full Size Table

Citation: Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases 2018; 6(8): 161-166
URL: https://www.wjgnet.com/2307-8960/full/v6/i8/161.htm
DOI: https://dx.doi.org/10.12998/wjcc.v6.i8.161